跳至主要内容
临床试验/ISRCTN12178605
ISRCTN12178605进行中(未招募)1 期

Phase I trial: Quotient code QSC207871 [the full scientific title will be published within 30 months after the end of the trial]

ovartis Pharma AG0 个研究点目标入组 43 人开始时间: 2024年8月12日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
43

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

排除标准

  • The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

研究者

相似试验

已完成
1 期
Phase I trial Quotient Code: QSC207682The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.Not Specified
ISRCTN10750305Constellation Pharmaceuticals (United States)8
进行中(未招募)
1 期
Phase I trial, Quotient Code: QSC208063The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
ISRCTN17473850Trevena, Inc.72
进行中(未招募)
1 期
Phase I trial, Quotient Code: QSC300720The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
ISRCTN57359805Veradermics Inc16
进行中(未招募)
1 期
Phase I trial, Quotient code: QSC205601The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.
ISRCTN10521680ovartis (Switzerland)116
进行中(未招募)
1 期
Phase I trial, Quotient code: QSC301137, Sponsor code: LMNL6511C1001The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
ISRCTN46791858iminal BioSciences (United Kingdom)88